Gdynia 2016 Nat Commun: Difference between revisions
No edit summary |
Beno Marija (talk | contribs) No edit summary ย |
||
(2 intermediate revisions by 2 users not shown) | |||
Line 6: | Line 6: | ||
|journal=Nat Commun | |journal=Nat Commun | ||
|abstract=The high-mobility group box 1 (HMGB1) protein has a central role in immunological antitumour defense. Here we show that natural killer cell-derived HMGB1 directly eliminates cancer cells by triggering metabolic cell death. HMGB1 allosterically inhibits the tetrameric pyruvate kinase isoform M2, thus blocking glucose-driven aerobic respiration. This results in a rapid metabolic shift forcing cells to rely solely on glycolysis for the maintenance of energy production. Cancer cells can acquire resistance to HMGB1 by increasing glycolysis using the dimeric form of PKM2, and employing glutaminolysis. Consistently, we observe an increase in the expression of a key enzyme of glutaminolysis, malic enzyme 1, in advanced colon cancer. Moreover, pharmaceutical inhibition of glutaminolysis sensitizes tumour cells to HMGB1 providing a basis for a therapeutic strategy for treating cancer. | |abstract=The high-mobility group box 1 (HMGB1) protein has a central role in immunological antitumour defense. Here we show that natural killer cell-derived HMGB1 directly eliminates cancer cells by triggering metabolic cell death. HMGB1 allosterically inhibits the tetrameric pyruvate kinase isoform M2, thus blocking glucose-driven aerobic respiration. This results in a rapid metabolic shift forcing cells to rely solely on glycolysis for the maintenance of energy production. Cancer cells can acquire resistance to HMGB1 by increasing glycolysis using the dimeric form of PKM2, and employing glutaminolysis. Consistently, we observe an increase in the expression of a key enzyme of glutaminolysis, malic enzyme 1, in advanced colon cancer. Moreover, pharmaceutical inhibition of glutaminolysis sensitizes tumour cells to HMGB1 providing a basis for a therapeutic strategy for treating cancer. | ||
|keywords=Human colorectal adenocarcinoma SW480 cells, Human colon carcinoma HCT116 cells, Human colorectal adenocarcinomaHT29 cells | |||
|mipnetlab=DE Heidelberg Mairbaeurl H | |mipnetlab=DE Heidelberg Mairbaeurl H | ||
}} | }} | ||
{{Labeling | {{Labeling | ||
|area=Respiration, Pharmacology;toxicology | |area=Respiration, Pharmacology;toxicology | ||
|diseases=Cancer | |||
|injuries=Cell death | |||
|organism=Human | |organism=Human | ||
|tissues=Endothelial;epithelial;mesothelial cell | |tissues=Endothelial;epithelial;mesothelial cell, Other cell lines | ||
|preparations=Permeabilized cells | |preparations=Permeabilized cells | ||
| | |couplingstates=ROUTINE | ||
| | |pathways=ROX | ||
|instruments=Oxygraph-2k | |instruments=Oxygraph-2k | ||
|additional= | |additional=2016-05 | ||
}} | }} |
Latest revision as of 10:42, 9 November 2016
Gdynia G, Sauer SW, Kopitz J, Fuchs D, Duglova K, Ruppert T, Miller M, Pahl J, Cerwenka A, Enders M, Mairbรคurl H, Kamiลski MM, Penzel R, Zhang C, Fuller JC, Wade RC, Benner A, Chang-Claude J, Brenner H, Hoffmeister M, Zentgraf H, Schirmacher P, Roth W (2016) The HMGB1 protein induces a metabolic type of tumour cell death by blocking aerobic respiration. Nat Commun 7:10764. |
Gdynia G, Sauer SW, Kopitz J, Fuchs D, Duglova K, Ruppert T, Miller M, Pahl J, Cerwenka A, Enders M, Mairbaeurl H, Kaminski MM, Penzel R, Zhang C, Fuller JC, Wade RC, Benner A, Chang-Claude J, Brenner H, Hoffmeister M, Zentgraf H, Schirmacher P, Roth W (2016) Nat Commun
Abstract: The high-mobility group box 1 (HMGB1) protein has a central role in immunological antitumour defense. Here we show that natural killer cell-derived HMGB1 directly eliminates cancer cells by triggering metabolic cell death. HMGB1 allosterically inhibits the tetrameric pyruvate kinase isoform M2, thus blocking glucose-driven aerobic respiration. This results in a rapid metabolic shift forcing cells to rely solely on glycolysis for the maintenance of energy production. Cancer cells can acquire resistance to HMGB1 by increasing glycolysis using the dimeric form of PKM2, and employing glutaminolysis. Consistently, we observe an increase in the expression of a key enzyme of glutaminolysis, malic enzyme 1, in advanced colon cancer. Moreover, pharmaceutical inhibition of glutaminolysis sensitizes tumour cells to HMGB1 providing a basis for a therapeutic strategy for treating cancer. โข Keywords: Human colorectal adenocarcinoma SW480 cells, Human colon carcinoma HCT116 cells, Human colorectal adenocarcinomaHT29 cells
โข O2k-Network Lab: DE Heidelberg Mairbaeurl H
Labels: MiParea: Respiration, Pharmacology;toxicology
Pathology: Cancer
Stress:Cell death
Organism: Human
Tissue;cell: Endothelial;epithelial;mesothelial cell, Other cell lines
Preparation: Permeabilized cells
Coupling state: ROUTINE
Pathway: ROX
HRR: Oxygraph-2k
2016-05